Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab

Clinical and Experimental Rheumatology

Volumn 29, Issue 4 SUPPL. 67, 2011, Pages

  Leccese, P ^a   Latanza, L ^b   D'Angelo, S ^a   Padula, A ^a   Olivieri, I ^a,c  

^a San Carlo Hospital of Potenza   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c SAN CARLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; INFLIXIMAB; MYDRIATIC AGENT; PREDNISONE; CORTICOSTEROID; STEROID;

ADULT; BEHCET DISEASE; CASE REPORT; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENITAL ULCER; HLA TYPING; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RETINA VASCULITIS; SLIT LAMP; UVEITIS; ARTICLE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; EYE FUNDUS; MOUTH DISEASE; PAPULE; PUSTULE; RECURRENT DISEASE; REMISSION; RETINITIS; SKIN DEFECT; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BEHCET SYNDROME; DRUG RESISTANCE; HUMANS; MALE; UVEITIS;

EID: 80855165266     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. SFIKAKIS PP. KAKLAMANIS PH, ELEZOGLOU A et al.: Infliximab for recurrent, sight-threatening ocular inflammation in Adamantidiades-Behçet's disease. Ann Intern Med 2004; 140: 404-6. (Pubitemid 38268925)
2. OHNO S, NAKAMURA S, HORI S et al.: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362-8. (Pubitemid 38879203)
3. LINDSTEDT EW, BAARSMA GS, KUUPERS RW, VAN HAGEN PM: Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005; 89: 533-6. (Pubitemid 40569703)
4. TUGAL-TUTKUN I, MUDUN A, URGANCIOGLU M et al.: Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005; 52: 2478-84. (Pubitemid 41117435)
5. MUSHTAQ B, SAEED T, SITUNAYAKE RD, MURRAY PI: Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 2007; 21: 824-5. (Pubitemid 46909189)
6. SFIKAKIS PP, MARKOMICHELASIS N, ALPSOY E et al.: Anti-TNF therapy in the management of Behçet's disease review and basis for recommendations. Rheumatology (Oxford) 2007; 46: 736-41. (Pubitemid 47061701)
7. OLIVIERI I, PADULA A, LECCESE P, D'ANGELO S, GIASIV: Long-lasting remission of severe Behçet's disease after the end of infliximab therapy. J Rheumatol 2009; 36: 855.
8. HATEMI G, SILMAN A, BANG D et al.: EULAR recommendations for the management of Behçet's disease. Ann Rheun Dis 2008; 67: 1656-62.
9. OLIVIERI I, D'ANGELO S, PADULA A, LECCESE P. MENNILLO GA: Successful treatment of recalcitrant genital ulcers of Behçet's disease with abalimumab after failure of infliximab and etanercept. Clin Exp Rheumatol 2009; 27 (Suppl. 53): SI 12.
10. TAKASE K, OHNO S, IDEGUCHI H, UCHIO E, TAKENO M, ISHIGATSUBO Y: Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease related uveitis. Rheumatol Int 2011; 31: 243-5 [Epub 2009 Oct 9].